0

Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

Understanding Cell Death May Bring New Life To Kidney Treatment

  • 작성자한진
  • 작성일2006-04-21 20:05:25
  • 조회수2192
  • 첨부파일첨부파일
Finding how two proteins conspire to get kidney cells to self-destruct when oxygen supplies are low may one day improve dismal mortality rates for ischemic renal failure, researchers say. Dehydration, low blood pressure, septic shock, trauma or removing a kidney for transplantation can temporarily halt or reduce blood and oxygen supplies, says Dr. Zheng Dong, cell biologist at the Medical College of Georgia. Ischemia leads to cell suicide or apoptosis, particularly in the energy-consuming tubular cells of the kidneys, he says. Fifty percent mortality rates from resulting ischemic renal failure haven’t changed in nearly as many years, Dr. Dong says. Tubular cells – which have the daunting daily task of reabsorbing nearly 50 gallons of usuable fluid volume, including salt and glucose the kidneys filter from the blood every 24 hours – are particularly vulnerable to apoptosis and injury, Dr. Dong says. “They are highly energy-dependent,” he says. “That is why when you shut off the blood supply, these cells are quickly, irreversibly damaged and they die.” Tubular cell injury and death is why kidneys are so vulnerable, for example in critically ill patients. It’s in this oxygen-deprived environment that two proteins, Bid and Bax – each a known killer in its own right – are activated and may partner to induce cell death. The killing proteins are pervasive, particularly in the kidneys, says Dr. Dong, who recently received a $1 million grant from the National Institute of Diabetes & Digestive & Kidney Diseases, to better understand their role in cell death during ischemic renal failure. In both cell culture and animal models of ischemic renal injury, Dr. Dong and his colleagues have found Bid is cleaved or cut, releasing active fragments. Although he still doesn’t know what cuts Bid, that act enables the protein to move from its usual place in the outer region of the cell to inside its powerhouses or mitochondria. Cleaving results in what Dr. Dong calls truncated Bid or “tBid,” which may interact with Bax and produce a conformational change. “Now Bax can move,” says Dr. Dong, and it also heads straight for the mitochondria, which normally feed and oxygenate cells. Once inside, Bax bits re-collect, forming a complex capable of making a hole in the mitochondria and enabling molecules, such as cytochrome C, a major enabler of cell respiration, to escape. “This process as we have shown probably is mediated by Bax, and now we have found that Bid can be a critical trigger of Bax,” Dr. Dong says. A Bid knockout mouse model, developed at the University of Pittsburgh, helps illustrate the synergism. Without Bid, there is less apoptosis while kidney function and survival rates significantly improve. Also, interestingly, without Bid, cell regeneration that helps the kidney recover from ischemia is slower, he notes. The kidney normally has some capacity to regenerate, with surviving cells quickly stretching to cover holes left by dead cells and later dividing to form more cells for tissue repair. “Within a couple of hours, neighboring cells will stretch to cover the wound, to take up the work of the dying cells,” Dr. Dong says. Unfortunately, while some kidney cells are working hard to make up the loss, Bid and Bax continue to trigger apoptosis and eventually the kidney fails, he says. One goal is finding the protease that cleaves Bid – he doesn’t think it’s Bax – and following the ensuing cascade to better understand the process so it can be manipulated to stop needless cell death or, in the case of cancer, enhance self-destruction. In related research, Dr. Dong’s lab is studying kidney damage caused by the common chemotherapeutic agent, Cisplatin, used for testicular, ovarian and small cell lung cancer, head and neck tumors and more. Renal function is closely monitored while on therapy because of the drug’s known side effects in the kidney. “We want to see how the drug can kill kidney cells and if we can find a protective mechanism to prevent kidney cell death without stopping cancer cell death,” says Dr. Dong. He thinks the answer may be in the differences between healthy and cancerous cells.
Total406 [ page4/28 ]
No. 제목 작성자 작성일 조회수
361 제 6회 논문연구계획서 발표대회: 최성우 학생 우수상 수상 첨부파일 2010.04.28 최성우 2010.04.28 2,859
360 다이어트 운동과 AMPK와의 관계 2010.04.20 고태희 2010.04.20 4,609
359 인슐린 생산 베타세포 재생 가능 2010.04.06 김형규 2010.04.06 3,453
358 축하합니다. 김나리 선생님: 2010 국제협력연구사업 선정 2010.03.05 한진 2010.03.05 3,581
357 동맥경화 촉진 유전자 찾아냈다...이화여대 오구택 교수 2010.02.25 허혜진 2010.02.25 3,293
356 국지적 항산화단백질 조절 메커니즘 규명...국가과학자 이서구 이화여대 교수 2010.02.25 허혜진 2010.02.25 3,295
355 Prog Biophys Mol Biol논문 accept소식 2010.02.20 박원선 2010.02.20 2,662
354 Pflugers Arch논문 accept소식 2010.02.17 박원선 2010.02.17 1,912
353 장미 박사님 질병관리본부 합격 2010.02.16 박원선 2010.02.16 2,976
352 Seaons's Greetings to ALL 첨부파일 2010.01.04 한진 2010.01.04 1,663
351 안준석 제 5회 부산미래과학자상 수상자 선정 첨부파일 2009.12.02 한진 2009.12.02 4,677
350 인슐린 신호전달과 미토콘드리아 기능을 통합시키는 Foxo1 첨부파일 2009.11.24 홍다혜 2009.11.24 5,358
349 심혈관·대사질환 10대 주목 프로젝트 선정 2009.11.16 한진 2009.11.16 2,357
348 JPS논문 accept소식 2009.11.06 박원선 2009.11.06 1,724
347 Bone논문 accept소식 2009.11.05 박원선 2009.11.05 2,369
처음이전 1 2 3 4 5 6 7 8 9 10 다음 마지막